Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CALENDAR OF EVENTS, STOCK/OTHER MARKET NEWS, SHAREHOLDER RIGHTS PLANS, SHAREHOLDER RIGHTS PLANS, MISCELLANEOUS

Helix BioPharma Corp. Extends Period to Exercise Warrants


RICHMOND HILL, Ontario, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend the exercise period of a total of 4,546,000 outstanding common share purchase warrants (the "Warrants"), all of which are held by arm's length parties. The Warrants were issued pursuant to a private placement of the Company completed on November 1, 2013, and represent approximately 4.4% of the Company's issued and outstanding common shares.

Each Warrant currently entitles the holder to purchase one common share of the Company at an exercise price of $1.61 at any time until October 31, 2018. Subject to TSX approval, the expiry date of the Warrants will be extended by two years to October 31, 2020. The exercise price of the Warrants will remain unchanged at $1.61. If approved by the TSX, the effective date of the amendment will be October 31, 2018. The Company will not extend 122,000 warrants held directly or indirectly by insiders of the Company.

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor ("CAR") based cell therapies. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Investor Relations

Helix BioPharma Corp.
9120 Leslie Street, Suite 205
Richmond Hill, Ontario, L4B 3J9
Tel: 905-841-2300
Email: [email protected]

Cautionary Statements

This news release may contain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to Helix's operations and strategy, its research and development activities and statements regarding the expected use of net proceeds of the private placement. Forward-looking statements, which may be identified by words including, "without limitation", "believe", "subject to", "will", "should" "may", "promising" and other similar expressions, are intended to provide information about management's current plans and expectations.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, risks inherent in Helix's research and development activities and those risks and uncertainties affecting the company, as more fully described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the factors described in the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.


These press releases may also interest you

at 07:45
QuantaSing Group Limited ("QuantaSing" or the "Company"), a leading online learning service provider in China, today announced that Tim Xie, the Company's Chief Financial Officer and Director, will present live at the AI & Technology Hybrid Investor...

at 07:45
Canadian Apartment Properties Real Estate Investment Trust ("CAPREIT") announced today that it has closed on four non-core Canadian dispositions for combined consideration of $83.5 million, and has entered into an agreement to dispose of an...

at 07:45
HEALWELL AI achieved annual revenue from continuing operations of $7.32 million in fiscal 2023. HEALWELL ended 2023 with a strong balance sheet, having secured approximately $29.5 million from convertible debt and equity financings.Since its relaunch...

at 07:45
On March 23rd, global lifestyle brand MINISO opened a vibrant new pop-up in Times Square, New York, the brand's second location in the iconic shopping district. Located next to the Disney Store at 1540 Broadway, New York, the new pop-up is a cuddly...

at 07:35
PHINIA Inc. , a leader in premium fuel systems, electrical systems and aftermarket parts, will report first quarter 2024 results on Thursday, April 25, 2024. PHINIA's earnings press release, earnings presentation and other materials will be available...

at 07:35
Consolidated copper production is expected to average 153,000i tonnes per year over the next three years, representing a 16% increase from 2023 and demonstrating Hudbay's strong and stable operating portfolio with three long-life operations in...



News published on and distributed by: